Page last updated: 2024-09-04

cositecan and dx 8951

cositecan has been researched along with dx 8951 in 2 studies

Compound Research Comparison

Studies (cositecan)	Trials (cositecan)	Recent Studies (post-2010) (cositecan)	Studies (dx 8951)	Trials (dx 8951)	Recent Studies (post-2010) (dx 8951)
20	5	2	73	18	15

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH	1
Bailly, C; Lansiaux, A	1

Other Studies

2 other study(ies) available for cositecan and dx 8951

Article	Year
New analogues of camptothecins. Activity and resistance. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
[A symphony for the camptothecins]. Bulletin du cancer, 2003, Volume: 90, Issue:3 Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan	2003

Article

Year

New analogues of camptothecins. Activity and resistance.

Annals of the New York Academy of Sciences, 2000, Volume: 922

Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2000

[A symphony for the camptothecins].

Bulletin du cancer, 2003, Volume: 90, Issue:3

Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan

2003